128 related articles for article (PubMed ID: 37606970)
1. Evaluation of belimumab in treatment of Chinese childhood-onset systemic lupus erythematosus: a prospective analysis from a multicentre study.
Wang L; Liang X; Cao Z; Wang D; Luo Y; Feng Y; Luo C; Zhi S; Huang Y; Fan Z; Wang C; Liu H; Liu J; Zhang T; Cheng Q; Xie X; Shuai L; Rong Z; Zeng P; Yu H; Lu M; Sun L; Yang S; Zhao D; Zhang W; Wu X; Li Q; Wang Y; Zhang Q; Yang J; Li X; Song H; Tang X
Rheumatology (Oxford); 2024 May; 63(5):1437-1446. PubMed ID: 37606970
[TBL] [Abstract][Full Text] [Related]
2. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Zhang F; Bae SC; Bass D; Chu M; Egginton S; Gordon D; Roth DA; Zheng J; Tanaka Y
Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
[TBL] [Abstract][Full Text] [Related]
3. Low disease activity-irrespective of serologic status at baseline-associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study.
Fanouriakis A; Adamichou C; Koutsoviti S; Panopoulos S; Staveri C; Klagou A; Tsalapaki C; Pantazi L; Konsta S; Mavragani CP; Dimopoulou D; Ntali S; Katsikas G; Boki KA; Vassilopoulos D; Konstantopoulou P; Liossis SN; Elezoglou A; Tektonidou M; Sidiropoulos P; Erden A; Sfikakis PP; Bertsias G; Boumpas DT
Semin Arthritis Rheum; 2018 Dec; 48(3):467-474. PubMed ID: 29555348
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of belimumab for the treatment of refractory childhood-onset systemic lupus erythematosus: A single-center, real-world, retrospective study.
Wang D; Shan C; Liu J; Zhang R; Zhu G; Gao T; Chang H; Gao S; Bai C; Nie N; Zhang Q; Lin Y
Front Immunol; 2022; 13():1067721. PubMed ID: 36591249
[TBL] [Abstract][Full Text] [Related]
5. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
Fan C; Yang T; Zheng S; Liao X; Xie R; Chen S; Li J
Front Immunol; 2024; 15():1423035. PubMed ID: 38947321
[TBL] [Abstract][Full Text] [Related]
6. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus.
Oon S; Huq M; Golder V; Ong PX; Morand EF; Nikpour M
Ann Rheum Dis; 2019 May; 78(5):629-633. PubMed ID: 30679152
[TBL] [Abstract][Full Text] [Related]
7. [Efficacy and safety of belimumab treatment in childhood-onset systemic lupus erythematosus].
Kang M; Zhu J; Xu YJ; Li SN; Lai JM
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3881-3885. PubMed ID: 36540927
[No Abstract] [Full Text] [Related]
8. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
[TBL] [Abstract][Full Text] [Related]
9. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Tanaka Y; Bass D; Chu M; Egginton S; Ji B; Roth D
Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
[No Abstract] [Full Text] [Related]
10. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
Wallace DJ; Stohl W; Furie RA; Lisse JR; McKay JD; Merrill JT; Petri MA; Ginzler EM; Chatham WW; McCune WJ; Fernandez V; Chevrier MR; Zhong ZJ; Freimuth WW
Arthritis Rheum; 2009 Sep; 61(9):1168-78. PubMed ID: 19714604
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
Stohl W; Schwarting A; Okada M; Scheinberg M; Doria A; Hammer AE; Kleoudis C; Groark J; Bass D; Fox NL; Roth D; Gordon D
Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
[TBL] [Abstract][Full Text] [Related]
12. Effect of belimumab in patients with systemic lupus erythematosus treated with low dose or no corticosteroids.
Lee YJ; Ahn SM; Hong S; Oh JS; Lee CK; Yoo B; Kim YG
Korean J Intern Med; 2024 Mar; 39(2):338-346. PubMed ID: 38031366
[TBL] [Abstract][Full Text] [Related]
13. Effects of Belimumab on Flare Rate and Expected Damage Progression in Patients With Active Systemic Lupus Erythematosus.
Iaccarino L; Bettio S; Reggia R; Zen M; Frassi M; Andreoli L; Gatto M; Piantoni S; Nalotto L; Franceschini F; Larosa M; Fredi M; Punzi L; Tincani A; Doria A
Arthritis Care Res (Hoboken); 2017 Jan; 69(1):115-123. PubMed ID: 27390293
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland.
von Kempis J; Duetsch S; Reuschling N; Villiger R; Villiger PM; Vallelian F; Schaer DJ; Mueller RB
Swiss Med Wkly; 2019 Feb; 149():w20022. PubMed ID: 30852830
[TBL] [Abstract][Full Text] [Related]
15. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
Ginzler EM; Wallace DJ; Merrill JT; Furie RA; Stohl W; Chatham WW; Weinstein A; McKay JD; McCune WJ; Zhong ZJ; Freimuth WW; Petri MA;
J Rheumatol; 2014 Feb; 41(2):300-9. PubMed ID: 24187095
[TBL] [Abstract][Full Text] [Related]
16. LLDAS is an attainable treat-to-target goal in childhood-onset SLE.
Wahadat MJ; van den Berg L; Timmermans D; van Rijswijk K; van Dijk-Hummelman A; Bakx S; Verkaaik M; Versnel MA; Kamphuis S
Lupus Sci Med; 2021 Dec; 8(1):. PubMed ID: 34969874
[TBL] [Abstract][Full Text] [Related]
17. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
Schwarting A; Dooley MA; Roth DA; Edwards L; Thompson A; Wilson B
Lupus; 2016 Dec; 25(14):1587-1596. PubMed ID: 27488472
[TBL] [Abstract][Full Text] [Related]
18. Long-term organ damage accrual and safety in patients with SLE treated with belimumab plus standard of care.
Bruce IN; Urowitz M; van Vollenhoven R; Aranow C; Fettiplace J; Oldham M; Wilson B; Molta C; Roth D; Gordon D
Lupus; 2016 Jun; 25(7):699-709. PubMed ID: 26936891
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
Brunner HI; Abud-Mendoza C; Mori M; Pilkington CA; Syed R; Takei S; Viola DO; Furie RA; Navarra S; Zhang F; Bass DL; Eriksson G; Hammer AE; Ji BN; Okily M; Roth DA; Quasny H; Ruperto N
RMD Open; 2021 Sep; 7(3):. PubMed ID: 34531304
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of belimumab treatment in patients with systemic lupus erythematosus in a clinical practice setting: Results from a 24-month OBSErve study in Argentina.
Babini A; Cappuccio AM; Caprarulo C; Casado G; Eimon A; Figueredo H; García MA; Magri S; Mannucci P; Perez Rodriguez S; Pons-Estel BA; Velozo EJ; Iglesias-Rodriguez M; Streger G
Lupus; 2020 Oct; 29(11):1385-1396. PubMed ID: 32791930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
